source
- AbbVie eyes pan-RAS market with up to $1.45 B option to acquire KestrelAbbVie announced it has signed an agreement that gives it the right to acquire Kestrel Therapeutics for up to $1.45 billion. The deal would give AbbVie access to Kestrel’s pipeline focused on pan-…
- Novartis CEO says Trump’s drug pricing plan creates a very difficult situation for makers and patientsNovartis chief executive Vas Narasimhan warned that the United States drug‑pricing policy under President Trump presents a "very difficult situation" for both drugmakers and patients. He said the…